Cite
HARVARD Citation
Faje, A. et al. (2019). Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. European journal of endocrinology. 181 (3), pp. 211-219. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Faje, A. et al. (2019). Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. European journal of endocrinology. 181 (3), pp. 211-219. [Online].